Therefore, we hypothesized that targeting STAT3 could reverse the resistant phenotype in tumor cells, thereby enhancing the anti-tumor effects of cisplatin treatment in HNSCC. The gene discussed is STAT3; the disease is head and neck squamous cell carcinoma.